Despite the established efficacy of HDAC1 inhibitors in NSCLC and the acknowledged interaction with PHF12, we thought that confirming the utility of these inhibitors does not necessarily imply PHF12’s central role. This evidence concerns the gene HDAC1 and non-small cell lung carcinoma.